natgillin/translations-raw huggingface dataset:
TAC = docetaxel, doxorubicin og cyclophosphamid FAC = 5-fluoruracil, doxorubicin and cyclophosphamid CI = Konfidensinterval; ER = østrogenreceptor PR = progesteronreceptor a ER/PR-negativ eller grad 3 eller tumorstørrelse >5 cm 
TAC = docetaxel, doxorubicin and cyclophosphamide FAC = 5-fluorouracil, doxorubicin and cyclophosphamide CI = confidence interval; ER = oestrogen receptor PR = progesterone receptor a ER/PR-negative or Grade 3 or tumour size >5 cm
Efter administration af docetaxel 100 mg/m givet som infusion over 1 time, fandtes den gennemsnitlige maksimale plasmakoncentration at være 3,7 mg/ml med et AUC på 4,6 h.g/ml. 
Following the administration of a 100 mg/m2 dose given as a one-hour infusion a mean peak plasma level of 3.7 µg/ml was obtained with a corresponding AUC of 4.6 h.µg/ml.
Den endelige analyse blev udført, da alle patienter havde nået deres 10 års opfølgningsbesøg (medmindre de havde en DFS hændelse eller tidligere udgik afopfølgning). 
The final analysis was performed when all patients had reached their 10-year follow-up visit (unless they had a DFS event or were lost to follow-up before).
De mest almindelige bivirkninger af Docetaxel Zentiva givet alene er: Fald i antallet af røde og hvide blodlegemer, hårtab, kvalme, opkastning, sår i munden, diarré og træthed. 
The most commonly reported adverse reactions of Docetaxel Zentiva alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.
Sygdoms-fri overlevelse (DFS) var det primære effektendepunkt og total overlevelse (OS) var det sekundære effektendepunkt. 
Disease-free survival (DFS) was the primary efficacy endpoint and overall survival (OS) was the secondary efficacy endpoint.
Docetaxel Zentiva må IKKE anvendes, hvis du er gravid eller planlægger at blive gravid, medmindre din læge udtrykkelig ønsker det. 
Docetaxel Zentiva must NOT be administered if you are pregnant unless clearly indicated by your doctor.
Docetaxel Zentiva i kombination med doxorubicin og cyclophosphamid er indiceret til adjuverende behandling af patienter med: 
Docetaxel Zentiva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:
Docetaxel Zentiva indeholder ethanol (alkohol) 
Docetaxel Zentiva contains ethanol (alcohol)
a Tid til hændelsesvariabler: stratificeret log-rank test. 
95% CI p-valuea* a Time to event variables: Stratified log-rank test.
Brug ikke dette lægemiddel efter den udløbsdato, der står på pakningen efter Exp. Udløbsdatoen er den sidste dag i den nævnte måned. 
Do not use this medicine after the expiry date which is stated on outer carton and on the label of the vial after EXP.
I patienter, som var 75 år eller ældre, blev der rapporteret en højere forekomst af neutropeni, anæmi, diarré, dyspnø, og infektioner i de øvre luftveje, sammenlignet med yngre patienter (mindst 10 % højere). 
In patients who were 75 years of age or older, when compared to younger patients, neutropenia, anemia, diarrhea, dyspnea and upper respiratory tract infection were reported with a greater incidence (at least 10% higher).
Det skal du vide, før du begynder at bruge Docetaxel Zentiva 
What you need to know before you use Docetaxel Zentiva
Gennemsnitsværdierne for den totale clearence og steady-state distributionsvolumen var henholdsvis 21 l/h/m og 113 l. Den interindividuelle variation i totalclearance var ca 50 %. 
Mean values for total body clearance and steady-state volume of distribution were 21 l/h/m2 and 113 l, respectively.
In vivo er docetaxels aktivitet uafhængig af behandlingsregimet og har eksperimentielt vist et bredt spektrum af antineoplastisk aktivitet over for murine og transplanterede humane tumorer. 
In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.
Alvorligheden af bivirkningerne ved Docetaxel Zentiva kan forøges, når Docetaxel Zentiva gives i kombination med andre kemoterapeutiske lægemidler. 
The severity of adverse events of Docetaxel Zentiva may be increased when Docetaxel Zentiva is given in combination with other chemotherapeutic agents.
Den opdaterede analyse blev udført, da alle patienter havde nået deres 10-års (median opfølgningstid var 10 år og 5 måneder) opfølgningsbesøg (medmindre de havde DFS eller tidligere var udgået fraopfølgning). 
The updated analysis was performed when all patients had reached their 10-year (median follow up time of 10 years and 5 months) follow-up visit (unless they had a DFS event or were lost to follow-up previously).
Ved kombination med docetaxel,var carboplatins clearence ca. 50 % højere end de værdier, der tidligere er rapporteret for carboplatin-monoterapi. 
When combined to docetaxel, the clearance of carboplatin was about 50% higher than values previously reported for carboplatin monotherapy.
Alt materiale, som har været brugt i forbindelse med fortynding og infusion, skal destrueres i overensstemmelse med lokale retningslinjer. 
All materials that have been utilised for dilution and administration should be disposed of according to standard procedures.
I kombination med trastuzumab er den anbefalede dosis af docetaxel 100 mg/m hver 3. uge med en ugentlig administration af trastuzumab. 
In combination with trastuzumab the recommended dose of docetaxel is 100 mg/m2 every three weeks, with trastuzumab administered weekly.
ER/PR-negativ eller grad 3 eller tumorstørrelse >5 cm 
PR = progesterone receptor a ER/PR-negative or Grade 3 or tumour size >5 cm
Menopausal status Præ-menopausal Post-menopausal 
Menopausal status
Medicinen hedder Docetaxel Zentiva. 
The name of this medicine is Docetaxel Zentiva.
ANVENDELSESMÅDE OG ADMINISTRATIONSVEJ(E) 
Method and route of administration
Hvis hætteglassene opbevares i køleskab, skal det nødvendige antal pakninger med Docetaxel Zentiva koncentrat til infusionsvæske, opløsning, stå ved stuetemperatur (under 25°C) i 5 minutter før brug. 
If the vials are stored under refrigeration, allow the required number of boxes of Docetaxel Zentiva concentrate for solution for infusion to stand below 25°C for 5 minutes before use.
Alvorlige hudproblemer såsom, Stevens-Johnson syndrom (SJS), toksisk epidermal nekrolyse (TEN) og akut generaliseret eksantematøs pustulose (AGEP) er blevet rapporteret med Docetaxel Zentiva: - SJS/TEN symptomer kan omfatte blærer, afskrælning eller blødning på dele af huden (herunder dine læber, øjne, mund, næse, kønsorganer, hænder eller fødder) med eller uden udslæt. 
Severe skin problems such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Acute Generalized Exanthematous Pustulosis (AGEP) have been reported with Docetaxel Zentiva: - SJS/TEN symptoms may include blistering, peeling or bleeding on any part of your skin (including your lips, eyes, mouth, nose, genitals, hands or feet) with or without a rash.
Docetaxel Zentiva som enkeltstof 
Docetaxel Zentiva as single agent
3. uge 
3 years
Metastatisk hormonfølsom prostatakræft Den anbefalede dosis af docetaxel er 75 mg/m hver 3. uge i 6 perioder. 
Metastatic hormone-sensitive prostate cancer The recommended dose of docetaxel is 75 mg/m2 every 3 weeks for 6 cycles.
I studiet GEICAM9805 udviklede 3 patienter (0,6 %) i TAC-armen og 3 patienter (0,6 %) i FACarmen kongestivt hjertesvigt i opfølgningsperioden. 
In GEICAM 9805 study, 3 patients (0.6 %) in TAC arm and 3 patients (0.6 %) in FAC arm developed congestive heart failure during the follow-up period.
Med en hazard ratio < 1 kan docetaxel + cisplatin+5-FU anvendes med fordel *Cox model (tilpasning til primær tumor, T og N kliniske stadier og PSWHO) **Logrank test *** Chi-square-test 
Hazard ratio (95% CI) **p-value A hazard ratio of less than 1 favours docetaxel + cisplatin + 5-FU *Cox model (adjustment for Primary tumour site, T and N clinical stages and PSWHO) **Log rank test *** Chi-square test
Der er rapporter om sjældne tilfælde af ototoksicitet, nedsat hørelse og/eller tab af hørelse. 
Ear and labyrinth disorders Rare cases of ototoxicity, hearing impaired and/or hearing loss have been reported.
Der er ingen relevant anvendelse af Docetaxel Zentiva i den pædiatriske population til indikationerne brystkræft, ikke-småcellet lungekræft, prostatakræft, gastrisk karcinom samt hoved- og halskræft med undtagelse af type II og III lavt differentieret nasofaryngealt karcinom.. 
There is no relevant use of Docetaxel Zentiva in the paediatric population in the indications breast cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head and neck cancer, not including type II and III less differentiated nasopharyngeal carcinoma.
tilfælde af grad 4-trombocytopeni bør dosis af docetaxel reduceres fra 75 mg/m til 60 mg/m 
In case of Grade 4 thrombocytopenia the docetaxel dose should be reduced from 75 to 60 mg/m2.
Som førstebehandling indgives 75 mg/m doxetaxel i kombinationsbehandling med doxorubicin (50 mg/m 
In first-line treatment, docetaxel 75 mg/m2 is given in combination therapy with doxorubicin (50 mg/m2).
Docetaxel Zentiva i kombination med androgen deprivationsbehandling, med eller uden prednison eller prednisolon, er indiceret til behandling af patienter med metastatisk hormonfølsom prostatakræft. 
Docetaxel Zentiva in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormonesensitive prostate cancer.
• Induktionskemoterapi efterfulgt af strålebehandling (TAX 323) Systemorganklasser i henhold til MedDRAdatabasen 
• Induction chemotherapy followed by radiotherapy (TAX 323) MedDRA system organ classes
Patienter med en udgangsværdi for neutrofile værdier på < 1.500 celler/mm 
Patients with baseline neutrophil count of < 1,500 cells/mm3.
I dette kliniske studium randomiseredes 255 patienter til behandling med docetaxel (75 mg/m² som en 1-times intravenøs infusion hver 3. uge) og capecitabin (1250 mg/m to gange daglig i 2 uger efterfulgt af en uges pause). 
In this study, 255 patients were randomised to treatment with docetaxel (75 mg/m2 as a 1 hour intravenous infusion every 3 weeks) and capecitabine (1250 mg/m2 twice daily for 2 weeks followed by 1-week rest period).
Patienter bør ikke genbehandles med efterfølgende cyklusser af docetaxel indtil neutrofil-antallet gendannes til et niveau  1.500 celler/mm og blodplader gendannes til et niveau 
Patients should not be retreated with subsequent cycles of docetaxel until neutrophils recover to a level > 1,500 cells/mm3 and platelets recover to a level > 100,000 cells/mm3.
Hjælpestoffer: Polysorbat 80, vandfri ethanol (læs indlægssedlen for yderligere information) og citronsyre. 
LIST OF EXCIPIENTS Excipients: polysorbate 80, ethanol anhydrous (see leaflet for further information) and citric acid.
Efter 10 års opfølgning i TAX 316 studiet blev akut leukæmi rapporteret hos 3 ud af 744 TACpatienter (0,4 %) og hos 1 ud af 736 FAC-patienter (0,1 %). 
After 10 years of follow up in study TAX316, acute leukaemia was reported in 3 of 744 TAC patients (0.4%) and in 1 of 736 FAC patients (0.1%).
De mest almindeligt rapporterede bivirkninger med docetaxel var: Neutropeni (som var reversibel og ikke kumulativ, median-dagen til nadir var 7 dage og median-varigheden af alvorlig neutropeni ( 500 celler/mm 
The most commonly reported adverse reactions of docetaxel alone are: neutropenia (which was reversible and not cumulative; the median day to nadir was 7 days and the median duration of severe neutropenia (< 500 cells/mm3) was 7 days), anaemia, alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia.
Docetaxel Zentiva er et antineoplastisk stof, og ligesom andre potentielle toksiske stoffer skal det behandles med forsigtighed ved håndtering og tilberedning af Docetaxel Zentiva-opløsningerne. 
Docetaxel Zentiva is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel Zentiva solutions.
Må ikke opbevares ved temperaturer over 25 ºC. 
SPECIAL STORAGE CONDITIONS Do not store above 25°C.
• Ved behandling af prostatakræft kan Docetaxel Zentiva indgives i kombination med prednison eller prednisolon. 
- For the treatment of prostate cancer, Docetaxel Zentiva is administered in combination with prednisone or prednisolone.
Den nødvendige mængde Docetaxel Zentiva koncentrat til infusionsvæske, opløsning, skal via en enkelt injektion (et skud) injiceres i en 250 ml infusionspose eller -flaske indeholdende enten en 5 % glucoseinfusionsvæske eller en 0,9 % natriumchloridinfusionsvæske. 
The required volume of Docetaxel Zentiva concentrate for solution for infusion must be injected via a single injection (one shot) into a 250 ml infusion bag or bottle containing either 5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion.
måneder. 
2 years
Docetaxel Zentiva i kombination med cisplatin og 5-fluoruracil er indiceret til indledende behandling af patienter med inoperable, lokale, fremskredne skællede celle-carcinoma i hoved og hals. 
Docetaxel Zentiva in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Hvis Docetaxel Zentiva infusionskoncentrat eller infusionsvæske skulle komme på huden, så vask omgående og grundigt med sæbe og vand. 
If Docetaxel Zentiva concentrate or infusion solution should come into contact with skin, wash immediately and thoroughly with soap and water.
Feber (G3: 1%) Oral candidiasis Hypokalcæmi (G3: 0%) Hypofosfatæmi (G3-4: 1%) Hypokaliæmi (G3: 0%) 
Oral candidiasis Hypocalcaemia (G3: 0%) Hypophosphataemia (G3-4: 1%) Hypokalaemia (G3: 0%)
• Ved behandling af lungekræft kan Docetaxel Zentiva enten indgives alene eller i kombination med cisplatin. 
- For the treatment of lung cancer, Docetaxel Zentiva could be administered either alone or in combination with cisplatin.
Docetaxel Zentiva i kombination med cisplatin og 5-fluoruracil er indiceret til behandling af patienter med metastatisk gastrisk adenokarcinom, inklusive adenokarcinom i den gastrooesophageale forbindelse, som ikke tidligere har fået kemoterapi mod metastatisk sygdom. 
Docetaxel Zentiva in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
445 patienter med KPS  70 blev behandlet med enten docetaxel (T) (75 mg/m2 på dag 1) i kombination med cisplatin (C) (75 mg/m på dag 1) og 5-fluoruracil (F) (750 mg/m pr. dag i 5 dage) 
A total of 445 patients with KPS > 70 were treated with either docetaxel (T) (75 mg/m2 on day 1) in combination with cisplatin (C) (75 mg/m2 on day 1) and 5-fluorouracil (F) (750 mg/m2 per day for 5 days) or cisplatin (100 mg/m2 on day 1) and 5-fluorouracil (1000 mg/m2 per day for 5 days).
Alopeci (G3: 3%) Negleforandringer (G3: 1%) 
Alopecia (G3: 3%)a Nail changes (G3: 1%)
• Docetaxel 30 mg/m administreret ugentlig i de første 5 uger i en 6 ugers behandlingsrunde i 5 
• Docetaxel 30 mg/m2 administered weekly for the first 5 weeks in a 6 week cycle for 5 cycles.
3) i mere end 7 dage i løbet af en docetaxelbehandling, anbefales det at reducere dosis i de efterfølgende cyklusser eller at tage passende symptomatiske forholdsregler (se pkt. 
In the case of severe neutropenia (< 500 cells/mm3 for seven days or more) during a course of docetaxel therapy, a reduction in dose for subsequent courses of therapy or the use of appropriate symptomatic measures are recommended (see section 4.2).
• Mitoxantrone 12 mg/m hver 3. uge i 10 behandlingsrunder. 
• Mitoxantrone 12 mg/m2 every 3 weeks for 10 cycles.
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. 
- If you get any side effects, talk to your doctor, hospital pharmacist or nurse.
• Ved behandling af tidlig brystkræft med eller uden lymfeknuder, kan Docetaxel Zentiva anvendes i kombination med doxorubicin eller cyclophosphamid. 
- For the treatment of early breast cancer with or without lymph node involvement, Docetaxel Zentiva could be administered in combination with doxorubicin and cyclophosphamide.
Hvis Docetaxel Zentiva infusionskoncentrat eller infusionsvæske skulle komme i kontakt med slimhinderne, så vask omgående og grundigt med vand. 
If Docetaxel Zentiva concentrate or infusion solution should come into contact with mucous membranes, wash immediately and thoroughly with water.
Docetaxel Zentiva i kombination med doxorubicin og cyclophosphamid: Adjuverende behandling 
Docetaxel Zentiva in combination with doxorubicin and cyclophosphamide: adjuvant therapy
Docetaxel Zentiva i kombination med doxorubicin 
Docetaxel Zentiva in combination with doxorubicin
• Standarpleje + docetaxel 75 mg/m², administreret hver 3. uge i 6 perioder 
• Standard of care + docetaxel 75 mg/m², administered every 3 weeks for 6 cycles
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med Docetaxel Zentiva i alle undergrupper af den pædiatriske population ved brystkræft, ikkesmåcellet lungekræft, prostatakræft, gastrisk adenokarcinom og hoved- og halskræft med undtagelse af type II og type III lavt differentieret nasofaryngealt karcinom (se pkt. 
The European Medicines Agency has waived the obligation to submit the results of studies with Docetaxel Zentiva in all subsets of the paediatric population in breast cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head and neck cancer, not including type II and III less differentiated nasopharyngeal carcinoma (see section 4.2 for information on paediatric use).
Hyppigheden af grad 4 neutropeni, febril neutropeni og neutropenisk infektion blev reduceret hos patienter der fik primær G-CSF-profylakse (se pkt. 
The incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis (see section 4.8).
I kombination med capecitabin er den anbefalede Docetaxel Zentiva-dosis 75 mg/m2 hver 3. uge kombineret med capecitabin 1250 mg/m to gange daglig (indenfor 30 minutter efter et måltid) i 2 uger efterfulgt af en uges pause. 
In combination with capecitabine, the recommended dose of docetaxel is 75 mg/m2 every three weeks, combined with capecitabine at 1250 mg/m2 twice daily (within 30 minutes after a meal) for 2 weeks followed by a 1-week rest period.
Docetaxel Zentiva i kombination med prednison eller prednisolon er indiceret til behandling af patienter med metastatisk kastrationsresistent prostatakræft. 
Docetaxel Zentiva in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
Patienter i docetaxel-armen fik docetaxel (T) 75 mg/m efterfulgt af cisplatin (P) 75 mg/m efterfulgt af 5-fluoruracil 750 mg/m daglig som en kontinuerlig infusion i 5 dage. 
Patients on the docetaxel arm received docetaxel (T) 75 mg/m2 followed by cisplatin (P) 75 mg/m2 followed by 5-fluorouracil (F) 750 mg/m2 per day as a continuous infusion for 5 days.
• Induktions kemoterapi efterfulgt af strålebehandling (TAX 323) Sikkerheden og effekten af docetaxel i den indledende behandling af patienter med pladecellecarcinom i hovedet og halsen (SCCHN) blev evalueret i et fase III, multicenter, åbent, randomiseret studie (TAX323). 
• Induction chemotherapy followed by radiotherapy (TAX323) The safety and efficacy of docetaxel in the induction treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a phase III, multi-centre, open-label, randomised study (TAX323).
Forsigtighedsregler ved behandling af kastrationsresistent prostatakræft Ud af 333 patienter behandlet med docetaxel hver tredje uge i et prostatakræftstudium (TAX 327), var 209 patienter 65 år eller derover og 68 patienter var ældre end 75 år. 
Cautions for use in castration-resistant prostate cancer Of the 333 patients treated with docetaxel every three weeks in a prostate cancer study (TAX 327), 209 patients were 65 years of age or greater and 68 patients were older than 75 years.
Som ved alle andre parenterale lægemidler skal Docetaxel Zentiva infusionsvæske kontrolleres visuelt for uklarheder, og opløsninger med udfældning skal kasseres. 
As with all parenteral products, Docetaxel Zentiva infusion solution should be visually inspected prior to use, solutions containing a precipitate should be discarded.
I dette studie viste AT-armen en hyppigere forekomst af alvorlig neutropeni (90 % versus 68,6 %), febril neutropeni (33,3 % versus 10 %), infektion (8 % versus 2,4 %), diarré (7,5 % versus 1,4 %), asteni (8,5 % versus 2,4 %) og smerter ((2,4 % versus 0 %) end AC-armen. 
In this study, AT arm showed a higher incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3% versus 10%), infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia (8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm. On the other hand, AC arm showed a higher incidence of severe anaemia (15.8% versus 8.5%) than AT arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease  20% (13.1% versus 6.1%), absolute LVEF decrease  30% (6.2% versus 1.1%).
Med docetaxel er der rapporteret tilfælde af kutan lupus erythematosus, bulløst udslæt såsom erythema multiforme og alvorlige kutane bivirkninger såsom Stevens-Johnson syndrom, toksisk epidermal nekrolyse og akut generaliseret eksantematøs pustulose. 
Cases of cutaneous lupus erythematosus, bullous eruptions such as erythema multiforme and severe cutaneous adverse reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) and Acute Generalized Exanthematous Pustulosis (AGEP) have been reported with docetaxel.
Dato for første markedsføringstilladelse: 20. april 2007 Dato for seneste fornyelse: 20. april 2012 
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 April 2007
På grund af risiko for skadelige påvirkninger af barnet skal amning derfor ophøre under behandling med docetaxel. 
Consequently, because of the potential for adverse reactions in nursing infants, breast-feeding must be discontinued for the duration of docetaxel therapy.
Docetaxel Zentiva i kombination med capecitabin 
Docetaxel Zentiva in combination with capecitabine
Sanofi-Aventis Deutschland GmbH 
Manufacturer(s) Sanofi-Aventis Deutschland GmbH Industriepark Höchst
Perifer sensorisk neuropati (≥G3: 2%) 
Peripheral sensory neuropathy (≥G3: 2%)a
Der skal tages hensyn hertil ved behandling af gravide og ammende kvinder, børn samt patienter i højrisikogrupper såsom patienter med leversygdom, eller epilepsi. 
To be taken into account in pregnant or breast-feeding women, in children and high-risk groups such as patients with liver disease, or epilepsy.
I studiet GEICAM 9805 forekom perifer sensorisk neuropati under behandlingen og fortsatte ind i opfølgningsperioden hos 10 patienter (1,9 %) i TAC-armen og 4 patienter (0,8 %) i FACarmen.Ved afslutningen af opfølgningsperioden (median opfølgningstid på 10 år og 5 måneder) blev det observeret, at perifer sensorisk neuropati fortsatte hos 3 patienter (0,6 %) i TAC-armen og hos 1 patient (0,2 %) i FAC-armen. 
In GEICAM 9805 study peripheral sensory neuropathy that started during the treatment period persisted into the follow-up period in 10 patients (1.9%) in TAC arm and 4 patients (0.8 %) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), peripheral sensory neuropathy was observed to be ongoing in 3 patients (0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.
Tabel over bivirkninger i højrisiko lokalt avanceret eller metastatisk hormonfølsom prostatakræft med DOCETAXEL 75 mg/m² i kombination med prednison eller prednisolon og androgen deprivationsbehandling (STAMPEDE studie). 
Tabulated list of adverse reactions in high-risk locally advanced or metastatic hormone-sensitive prostate cancer for DOCETAXEL 75 mg/m² in combination with prednisone or prednisolone and ADT (STAMPEDE study)